Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]
, 2019 Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M. +14 more
core +1 more source
Emerging treatments for essential thrombocythemia
Journal of Blood Medicine, 2011 Steven Okoli, Claire HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UKAbstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder ...
Okoli S, Harrison C
doaj
Essential thrombocythemia and acute myocardial infarction treated with rescue coronary angioplasty
Arquivos Brasileiros de Cardiologia, 1999 A 48-year-old man with essential thrombocythemia suffered an extensive anterior acute myocardial infarction; this is a rare association. A pharmacological thrombolysis was performed, without success.
Antonio Esteves Fº +4 more
doaj +1 more source
Blood, 2019 Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
A. Yacoub +33 more
semanticscholar +1 more source
Biomolecular and histological features in pediatric essential thrombocythemia: adequacy of who diagnostic criteria [PDF]
, 2017 Myeloproliferative neoplasms (MPN), Essential Thrombocythemia (ET), Polycythemia Vera (PV) and primary myelofibrosis (PMF), are clonal disorders of the hematopoietic stem cell.
Bertozzi, Irene
core +1 more source
Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40‐year‐old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long‐term safety for EF.
Maryam Sahebari +4 more
wiley +1 more source
Thromboembolic complication in Essential Thrombocythemia
The Pan African Medical Journal, 2012 The presenting symptoms of patients with essntial thrombocythemia are quite variable. After detection of thrombocytosis about 13 to 37 percent of patients relate symptoms due to hemorrhagic event, and about 22 to 84 percent of patients report ...
Zahra Mozaheb
doaj +1 more source
Blood Advances, 2019 In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET).
A. Carobbio +5 more
semanticscholar +1 more source
Improved Diagnosis of the Transition to JAK2V617F Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms [PDF]
, 2013 Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2V617F mutations.
Bianchini, Michele +6 more
core +3 more sources